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Background: Despite advances in understanding of clinical, genetic, and molecular aspects of multiple myeloma
(MM) and availability of more effective therapies, MM remains incurable. The autologous-allogeneic (auto-allo)
hematopoietic cell transplantation (HCT) strategy is based on combining cytoreduction from high-dose (chemo- or
chemoradio)-therapy with adoptive immunotherapy. However, conflicting results have been reported when an
auto-allo HCT approach is compared to tandem autologous (auto-auto) HCT. A previously published meta-analysis
has been reported; however, it suffers from serious methodological flaws.
Methods: A systematic search identified 152 publications, of which five studies (enrolling 1538 patients) met
inclusion criteria. All studies eligible for inclusion utilized biologic randomization.
Results: Assessing response rates by achievement of at least a very good partial response did not differ among the
treatment arms [risk ratio (RR) (95% CI) = 0.97 (0.87-1.09), p = 0.66]; but complete remission was higher in the auto-allo
HCT arm [RR = 1.65 (1.25-2.19), p = 0.0005]. Event-free survival did not differ between auto-allo HCT group versus
auto-auto HCT group using per-protocol analysis [hazard ratio (HR) = 0.78 (0.58-1.05)), p = 0.11] or using intention-to-treat
analysis [HR = 0.83 (0.60-1.15), p = 0.26]. Overall survival (OS) did not differ among these treatment arms whether analyzed
on per-protocol [HR = 0.88 (0.33-2.35), p = 0.79], or by intention-to-treat [HR = 0.80 (0.48-1.32), p = 0.39] analysis.
Non-relapse mortality (NRM) was significantly worse with auto-allo HCT [RR (95%CI) = 3.55 (2.17-5.80), p < 0.00001].
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Conclusion: Despite higher complete remission rates, there is no improvement in OS with auto-allo HCT; but this
approach results in higher NRM in patients with newly diagnosed MM. At present, totality of evidence suggests that an
auto-allo HCT approach for patients with newly diagnosed myeloma should not be offered outside the setting of a
clinical trial.
Keywords: Autologous hematopoietic stem cell transplantation, Allogeneic hematopoietic stem cell transplantation,
Multiple myeloma, Systematic reviewBackground
The past two decades witnessed major advances in treat-
ment of multiple myeloma (MM), including introduction
of high-dose therapy (HDT) (chemotherapy or chemora-
diotherapy), autologous hematopoietic cell transplantation
(auto-HCT), and other effective therapies including immu-
nomodulatory drugs or proteasome inhibitors, namely
bortezomib [1-5]. These new chemotherapeutic agents
when used in combinations, have led to improvement
in survival and a higher frequency and better quality of
response; but have not translated into cure of this
disease [3,4].
The concept of ″total therapy″ treatment approach for
patients with newly diagnosed MM, using multi-agent
induction regimens, tandem auto-auto HCT, and post-
transplantation maintenance resulted in progressive in-
crease in proportion of patients achieving complete
remission (CR) [6]. The Intergroupe Francophone du
Myelome (IFM) demonstrated that tandem auto-auto
HCT improves overall survival (OS) among patients with
myeloma, particularly if a very good partial response
(VGPR) is not achieved after undergoing the first auto-
HCT [7]. A meta-analysis by our group showed that tan-
dem auto-auto HCT versus single auto-HCT in previously
untreated MM results in improved response rates, but not
improved OS [8].
Badros et al. demonstrated the feasibility of offering
reduced-intensity conditioning (RIC) allogeneic (allo)-HCT
as a salvage strategy in 31 patients with relapsed MM [9].
Seventeen (55%) of 31 cases had received at least two auto-
HCT and 17 (55%) had progressive disease at time of
allografting [9]. Despite these adverse clinical features, 19
(61%) patients achieved CR or a near CR, with the 100-day
and overall non-relapse mortality (NRM) of 10% and
29%, respectively [9]. This suggests a beneficial graft-
versus-myeloma (GVM) effect mediated by alloreactive
donor T-cells is capable of disease control, even in MM
refractory to HDT. Gahrton et al. compared outcomes
of patients who received allo-HCT for relapsed MM during
1983–1993 and 1994–1998 showing improvement in NRM
and OS for patients allografted during the later time period
[10]. The authors speculate that earlier time to allografting
(10 months versus 14 months), for patients transplanted
during the later time period, probably contributed to thisbeneficial effect [10]. Similar results were recently reported
by Kumar et al., where 1 year OS post allo-HCT improved
in three successive eras (1989–1994, 1995–2000, and
2001–2005) and increased interval between time of MM
diagnosis and allografting was found to be an independent
adverse prognostic factor for OS [11].
Combining benefits of cytoreductive-therapy from
HDT and auto-HCT with adoptive immunotherapy
(from allo-HCT) forms the basis of auto-allo HCT treat-
ment strategy in patients with MM. Conflicting results,
however, have been noted when an auto-allo HCT
approach has been compared to an auto-auto HCT
strategy. A recent systematic review on the same issue
was performed by Armeson et al. [12] However, this
systematic review is limited by inclusion of an inappro-
priate study, in our opinion. That is, this systematic
review included the study by Garban et al. which was
not a true randomized controlled trial but rather repre-
sents comparisons from two parallel trials (IFM99-03
and IFM99-04) that enrolled allograft and autograft
recipients separately. Most importantly, the systematic
review by Armeson et al. did not attempt to evaluate the
methodological quality of included studies, which is the
one of the key reasons to conduct a systematic review.
Assessment of risk of bias in the systematic review
process provides explanations on whether the observed
findings are indeed the effect of the intervention or as a
result of bias. Accordingly, we performed a systematic
review of published studies comparing auto-auto HCT
with auto-allo HCT in patients with newly diagnosed
MM that addresses all the issues that were not
addressed in the systematic review by Armeson et al.
Results
Initial search yielded 152 references and 2 abstracts, of
which 149 were excluded for various reasons as shown in
Figure 1. Five studies (four full-manuscripts and one
abstract) enrolling a total of 1538 patients were eligible for
inclusion into this meta-analysis [13-17]. In one case [15],
we identified a complementary publication [18] which
provided longer follow-up on the originally published study.
Additionally, we excluded one manuscript [19] because it
was an indirect comparison (i.e. patients were enrolled
separately into two parallel trials, IFM99-03 and IFM99-04,
Medline search from 1966 to 
November 5, 2011
N = 152 references identified
N = 5 eligible studies
(4 manuscripts + 1 abstract)
(1538 patients)
Excluded= 149 references  
Not myeloma = 15
Not transplant-related = 28 
Not randomized to auto auto vs. 
auto allo = 41 
Reviews (systematic/meta-analysis, not-
systematic) = 63
Indirect comparison = 1
Duplicate = 1
Hand search of conference 
abstracts
N = 2 relevant abstracts
Figure 1 Flow-diagram depicting the identification and selection of eligible studies for inclusion in the systematic review.
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compared to each other). Finally, we excluded one abstract,
HOVON50/54, because patients on the control arm
received only a single auto HCT [20].
Patient, disease and treatment characteristics
Table 1 summarizes extracted data pertinent to patients0
disease and treatment characteristics. All studies allocated
patients to auto-allo HCT if an HLA-matched sibling
donor was available, except one [16] where matched
volunteer unrelated donors were permitted. For patients
undergoing tandem auto-auto HCT, high-dose melphalanTable 1 Characteristics of biologically randomized studies in
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first autograft in three studies [13,14,16], melphalan dose
ranging from 100 to 200 mg/m2 was used in one study
[15], and melphalan dose ranging from 140 (with total
body irradiation) to 200 mg/m2 was used in another study
[17]. For the second autograft, MEL200 was the preferred
regimen in two studies [13,16]. In the study by Bruno
et al. patients were offered a dose of melphalan ranging
from 100 to 200 mg/m2 [15], whereas Rosiñol et al.
allowed MEL200 or a combination of cyclophosphamide,
etoposide, BCNU [17]. Moreover, Björkstrand et al.
provided patients the option to undergo a secondtandem autologous versus autologous-allogeneic
myeloma
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autograft [14]. For the purpose of this meta-analysis, only
patients who received a second autograft were included in
analysis.
For patients who received an auto-allo HCT approach,
MEL200 was the preferred regimen for autografting in
four studies [13-16]. RIC regimen of 2 Gy TBI was the
preparative regimen in two studies [13,15]. Bjorkstrand
et al. combined fludarabine with 2 Gy TBI [14], while
the two remaining studies employed a RIC regimen with
fludarabine/melphalan for allo-HCT [16,17]. No specific
disease-risk eligibility criteria were required except in
one study which limited enrollment to patients with
deletion of chromosome 13q [16].
Methodological quality
Methodological quality of included studies is summarized
in Table 2. Briefly, all five studies utilized biologic
randomization. Four studies reported data on prognostic
factors and groups were balanced for presence of associated
prognostic risk factors [13-15,17,18] while one study did
not report data on prognostic factors [16]. None of the
studies reported whether all consecutive patients were
enrolled. Four studies had at least 1:2 ratio of auto-allo
HCT to auto-auto HCT patients while one study [17] had
a 1:3.4 ratio. None of the five studies reported blinding of
any study personnel. Four studies [13-15,17,18] reported
using the same reference time for assessing time
dependent outcomes while one study [16] did not report
a reference time. Three studies [13-15,18] reported
outcomes according to intention-to-treat (ITT) and
three studies [14,15,17,18] reported harms for patients
treated per protocol. One study reported a priori
expected difference, pre-specified α and β error, and
sample size calculation [13].
Benefits
Summary of all evidence is presented in Table 3.
Response rates
Response data was reported per protocol in four studies
and one study reported all outcomes according to both
ITT and per protocol [14]. Two studies [14,17] used
European Bone Marrow Transplantation (EBMT) cri-
teria [21] for response assessment; one study [13] used
International Uniform Response (IUR) Criteria [22],
while the (more stringent CR and PR) criteria used by
Bruno et al. was described [15]. One study did not
report how response was assessed [16].
As illustrated in Figure 2 A-C, the pooled results (three
studies [14,16,18] with 498 patients) showed no significant
difference in overall response rate (ORR) between auto-allo
HCT versus auto-auto HCT [risk ratio (RR) (95% confi-
dence interval [CI]) = 0.98 (0.92-1.05), p = 0.66]. There waslow heterogeneity between pooled studies for the outcome
of ORR (I2 =25%). The pooled results for CR from five
studies [13,14,16-18] (1130 patients) showed a statistically
significant benefit in treatment with auto-allo HCT over
auto-auto HCT [RR (95% CI) = 1.65 (1.25-2.19), p ≤ 0.001].
However, there was statistically significant heterogeneity
among pooled studies (I2 =68%). Results for at least VGPR
(one study [13] enrolling 522 patients) showed no signifi-
cant difference between either treatment strategy
[RR (95% CI) = 0.97 (0.87-1.09), p = 0.66].Event-free survival
None of the studies reported definitions for event-free
survival (EFS) or progression-free survival (PFS). For this
analysis, EFS data was used when reported, otherwise PFS
was substituted. As presented in Figure 3A, the pooled
results from three studies [13,14,18] (1229 patients) which
reported EFS according to ITT showed no significant diffe-
rence between treatment with auto-allo HCT versus auto-
auto HCT [hazard ratio (HR) (95% CI) = 0.83 (0.60-
1.15), p = 0.26]. Pooled results for three studies
[14,17,18] (409 patients) which reported EFS per protocol
also showed no significant difference in treatment with
auto-allo HCT [HR (95% CI) = 0.78 (0.58-1.05), p = 0.11]
compared with auto-auto HCT. Heterogeneity among
studies included in ITT analysis was significant
(I2 =77%) while heterogeneity in per-protocol analysis
was moderate (I2 =32%).Overall survival
As illustrated in Figure 3B, the pooled results (three
studies [13,14,18] enrolling 1229 patients) for OS
according to ITT showed no significant difference in
treatment with auto-allo HCT versus auto-auto HCT
[HR (95% CI) = 0.80 (0.48-1.32), p = 0.39]. The pooled
results from two studies [17,18] (214 patients) which
reported OS per-protocol also showed no significant
difference between the two treatment modalities
[HR (95% CI) = 0.88 (0.33-2.35), p = 0.79]. There was a
statistically significant heterogeneity whether OS was
analyzed according to ITT (I2 =85%) or per-protocol
(I2 =77%).Harms
Non-relapse mortality
Pooled results from four studies [13,14,17,18] (1047
patients) showed NRM was significantly worse with an
auto-allo HCT approach [RR (95% CI) = 3.55 (2.17-5.80),
p < 0.00001] compared to auto-auto HCT (Figure 4A).
There was no heterogeneity among included studies
(I2 =0%).
Table 2 Methodological quality of biologically randomized studies in tandem autologous versus autologous-allogeneic hematopoietic cell transplantation for
patients with multiple myeloma
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Table 3 Summary of evidence for tandem autologous versus autologous-allogeneic hematopoietic cell transplantation
in patients with multiple myeloma
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- Proportion 60.69 (50.65 to
70.29)
-
1 Selective outcome reporting; 2 Per-protocol reporting of benefits; 3 GVHD: graft-versus-host disease.
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Incidence of any acute graft-versus-host disease (GVHD)
was reported in one study [14] (91 patients) and the
proportion of patients undergoing auto-allo HCT with any
GVHD was 30.77% (95% CI 21.51-41.32). Incidence of
grade II-IV GVHD was reported in four studies
[13,14,17,18] (363 patients), and the pooled proportion of
patients undergoing auto-allo HCT with grade II-IV
GVHD was 28.26% (95% CI 20.65-36.55; see Figure 4B).
Heterogeneity among studies reporting grade II-IV GVHD
was borderline (I2 = 59%). Incidence of chronic GVHD was
reported in four studies [13,14,17,18] (356 patients), and
the pooled proportion of patients undergoing auto-allo
HCT with chronic GVHD was 60.69% (95% CI 50.65-
70.29; Figure 4C). Heterogeneity among studies reporting
chronic GVHD was significant (I2 = 67%).Sensitivity analysis/subgroup analysis
To assess robustness of the pooled results and explore
possible reasons for heterogeneity, additional sensitivity
and subgroup analyses were performed (see Table 4). To
evaluate robustness of response outcomes, sensitivity
analysis was performed according to response criteria
(EBMT [21], IUR [22], non-EBMT/IUR [15], and not
reported). There was no significant difference in ORR
or CR regardless of criteria used. Sensitivity analysis for
primary outcome of OS was performed according to all
elements of risk of bias. Significant differences in pooled
results were only detected when per protocol analysis of
OS in a study (104 patients) which included at least
1:2 ratio of auto-allo HCT versus auto-auto HCT [HR
(95% CI) = 0.55 (0.32-0.94) p = 0.03] was compared with
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Figure 2 A through 2C: Forest plot for response rates. Overall (A), complete (B) or at least very good partial response (C). The summary
estimate (risk ratio) from individual studies is indicated by rectangles with lines representing the 95% confidence intervals (CIs). The summary
pooled estimate from all studies is represented by the diamond and the stretch of the diamond indicates the corresponding 95% CI.
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auto HCT [HR (95% CI) = 1.51 (0.70-3.27) p = 0.30].
Sensitivity analysis according to risk of bias did not explain
reasons for observed heterogeneity of primary outcome.
For risk of random error, while one study [13] (710
patients) which reported sample size calculations
showed no difference in OS [HR (95% CI) = 1.24 (0.94-
1.64), p = 0.13], the pooled results from two studies
[14,18] (519 patients) which did not report sample size
calculations showed a significant OS benefit with use of
auto-allo HCT versus auto-auto HCT [HR (95% CI) = 0.64
(0.43-0.95), p = 0.03]. There was statistically significant
heterogeneity between the two studies which did not report
sample size calculations (I2 = 58%).
Discussion
Auto-HCT has been regarded as the standard of care for
younger myeloma patients [1,23]. However, much contro-
versy exists about the role and timing of allo-HCT in newly
diagnosed MM. Our meta-analysis indicates despite higherCR rates following an auto-allo HCT approach, there is no
apparent improvement in OS, whether comparative analysis
is performed as per-protocol or on ITT basis. This is likely
explained by significantly higher NRM associated with RIC
allo-HCT versus a second auto-HCT [RR (95% CI) = 3.55
(2.17-5.80), p < 0.00001]. Accordingly, further improve-
ments in the auto-allo HCT approach will require strategies
to significantly reduce NRM and augment anti-myeloma
effects. Not surprising, significant cause of NRM in the
auto-allo HCT arm resulted from development of acute
and/or chronic GVHD in these patients. For instance, in
the study by Krishnan et al. eight (13%) of 60 deaths were
attributed to GVHD [13]. Similarly, in the study by Rosiñol
et al., three (75%) of four cases of NRM were from com-
plications of acute GVHD [17]. This suggests that future
treatment strategies aimed at exploiting GVM effects, in
auto-allo HCT approach, should avoid exacerbating
GVHD at all costs. It is noteworthy that OS benefit with
an auto-allo HCT approach is limited to studies using
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Figure 3 A and 3B: Forest plot for event-free survival according to intent-to-treat analysis (A) and overall survival (B). The summary
estimate (hazard ratio) from individual studies is indicated by rectangles with lines representing the 95% confidence intervals (CIs). The summary
pooled estimate from all studies is represented by the diamond and the stretch of the diamond indicates the corresponding 95% CI.
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benefit in other studies might relate to use of more
intense conditioning which is associated with increased
regimen-related toxicity and mortality in those studies
[16,17]. It is important to indicate the largest trial by
Krishnan et al. [13] used 2 Gy TBI conditioning but was
also subject to referral bias, and to date has not reported
any survival benefit.
Conceptually, auto-allo HCT approach combines the ad-
vantage of cytoreduction from HDT from the first auto-
graft with the benefit of adoptive immunotherapy resulting
from the donor T cell alloreactivity. Notwithstanding, in
the study by Krishnan et al. 22 (37%) of 60 deaths in the
auto-allo HCT arm were still due to MM [13]. As a result,
future strategies should aim at achieving deeper remissions,
namely molecular remissions, or a state of minimal residual
disease, prior to moving forward with allografting. This
might entail evaluating novel potent therapies during the
peri-allografting phase. Moreover, designing more effective
regimens for allo-HCT, beyond 2 Gy TBI, is likely necessary
to improve outcomes.
In regards to using auto-auto HCT as the control arm for
comparison in these studies, one could argue that this
approach is not yet considered the standard of care in allpatients with newly diagnosed MM. In fact, outcomes from
various studies comparing single auto-HCT versus tandem
auto-auto approach have been discrepant [7,24,25] and a
published meta-analysis failed to show OS benefit with
tandem autografts [8].
A major limitation of all studies comparing auto-auto
HCT to auto-allo HCT is lack of detailed information
about disease/genetic risk stratification. Only one study
limited accrual to patients with deletion 13q detectable by
FISH [16]. However prognostic significance of 13q deletion
detected by FISH as opposed to conventional cytogenetics
remains questionable [26]. Whether an auto-allo HCT
approach might be beneficial for high-risk MM is not
known, and should be further assessed in future trials
[27-29]. We were not able to assess if auto-allo HCT
approach might be beneficial for high risk myeloma
patients as included studies did not report results
according to risk categories for all outcomes. An indi-
vidual patient data meta-analysis would be suitable to
answer this question. Furthermore, the results are
prone to outcome reporting bias as only three studies
reported OS data according to ITT [13,14,18] and an-
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Figure 4 A through 4C: Forest plot for non-relapse mortality (A), grade II-IV graft versus-host disease (B) and chronic graft versus-host
disease (C). The summary estimate (risk ratio/proportions) from individual studies is indicated by rectangles with lines representing the 95%
confidence intervals (CIs). The summary pooled estimate from all studies is represented by the diamond and the stretch of the diamond indicates
the corresponding 95% CI. For the proportional meta-analysis the diamond represents the pooled summary estimates and the 95% CI is indicated
by the line.
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systematic review by Armeson et al. as we excluded a
manuscript published by Garban et al. because it aimed at
comparing two parallel trials (IFM99-03 and the IFM99-04)
which enrolled allograft and autograft recipients separately
[12]. The objectives of the IFM99-03 trial were to evaluate
the feasibility and NRM of RIC allografting [19], whereas
the primary end point of IFM99-04 was to compare CR
rates achieved after the second auto HCT (with or without
anti–IL-6 monoclonal antibody BE-8). Additionally, we
excluded a cohort of high-risk patients reported by a study
by Krishnan et al. because the original aim of this study was
to assess progression-free survival among standard-risk
patients [13]. The investigators reported only partial data
on a smaller cohort of high-risk patients.Conclusions
Efforts at identifying particular subgroups of patients with
MM, based on prognostic clinical, biological, cytogenetic
and genetic risk factors, which are likely to benefit from an
auto-allo HCT approach is necessary to help refine the role
of this approach in MM. At the present, totality of evidence
suggests that an auto-allo HCT approach for patients with
newly diagnosed myeloma should not be offered outside
the setting of a clinical trial.
Methods
Identification of eligible studies
Any completed study in newly diagnosed MM patients
comparing auto-auto HCT versus auto-allo HCT was
eligible for inclusion in this systematic review. Studies
Table 4 Sensitivity analyses by response criteria and significant elements of quality
Subgroup Outcome Studies Patients HR or RR 95% CI Heterogeneity Test of Interaction
Tool used to capture response
EBMT criteria ORR (per-protocol) 1 195 0.96 (0.96–1.04) NA 0.26
Non-EBMT/IUR criteria 1 104 0.94 (0.82–1.08) NA
Criteria not reported 1 199 1.06 (0.95–1.18) NA
EBMT criteria CR (per-protocol) 2 305 2.05 (0.71–5.98) 85% 0.12
IUR criteria 1 522 1.29 (1.08–1.54) NA
Non-EBMT/IUR criteria 1 104 2.11 (1.23–3.63) NA
Criteria not reported 1 199 1.86 (1.29–1.54) NA
At least 1:2 ratio of auto-allo HCT versus auto-auto HCT
Yes OS (per-protocol) 1 104 0.55 (0.32–0.94) NA 0.04
No 1 110 1.51 (0.70–3.27) NA
Description of withdrawals/dropouts
Yes OS (ITT) 2 872 0.81 (0.34–1.92) 92% 0.93
No 1 357 0.77 (0.55–1.08) NA
Report calculation of sample size
Yes OS (ITT) 1 710 1.24 (0.94–1.64) NA 0.007
No 2 519 0.64 (0.43–0.95) 58%
Abbreviations: EBMT: European Group for Blood and Marrow Transplantation response criteria; IUR: International Uniform Response criteria; ORR: overall response
rate; CR: complete response; OS: overall survival; ITT: intention-to-treat; NA: not applicable.
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direct comparisons of tandem auto-auto HCT versus
auto-allo HCT were excluded.
A systematic search of MEDLINE database thru Nov 5,
2011, and pertinent conference proceedings (American
Society of Hematology, American Society of Clinical
Oncology, European Hematology Association, American
Society for Blood and Marrow Transplantation, and EBMT
Group) was conducted to identify relevant publications.
The following search strategy was used: (″Multiple
Myeloma″ [Mesh] AND ″Transplantation, Autologous″
[Mesh] AND ″Transplantation, Homologous″ [Mesh]). No
search limits were applied based on language.
Study selection and data extraction
Two authors (M.A.K-D and M.H.) appraised the list of
references and selected studies in consultation with other
authors (T.R. and A.K.). Disagreements were resolved by
consensus. Dual data extraction on clinical outcomes,
treatment benefits and harms, and methodological quality
of included studies was undertaken. Since biologic
randomization is not similar to traditional randomized con-
trolled trials, not all elements of risk of bias were applicable.
For methodological quality, we extracted data on the
following elements: comparability of two groups on all
aspects except the intervention (e.g. disease stage, age,
gender, etc.), enrollment of consecutive patients, enrollment
of patients in auto-allo and auto-auto group in at least 1:2
ratio, description of withdrawals and dropouts (if any),
blinding of study personnel and who was blinded (e.g. datacollectors, outcome assessors etc.), comparability of re-
ference time used for time-dependent outcomes between
treatment groups and analysis according to ITT principle
for benefits and per-protocol for adverse events. Clinical
outcomes analyzed included: response rates (ORR, CR and
VGPR), OS, EFS, NRM and GVHD. For purposes of this
review, OS was considered the primary outcome; response
rates, EFS, NRM and GVHD were considered secondary
outcomes.
Statistical analysis
Dichotomous data were summarized using RR based on
number of events and total number of patients and
pooled under random-effects model. For time-to event
data, HR and 95% CI were extracted when reported.
When authors did not report time-to-event estimates,
we extracted data from publication using methods
described by Tierney et al. [30]. Time-to-event data were
pooled using generic inverse variance under random-
effects model. For analysis of proportional data, methods
by Stuart et al. [31] were used to transform proportions
into a quantity according to Freeman-Tukey variant of
the arcsine square root transformed proportion [31].
Pooled proportion was calculated as a back-transform of
the weighted mean of the transformed proportions,
using random-effects model [31]. All data are reported
with 95% CI. Calculation of the I2 statistic was used to test
for heterogeneity. An I2 > 50% was considered statistically
significant heterogeneity [32]. To assess robustness of
the pooled results and explore possible reasons for
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http://www.jhoonline.org/content/6/1/2heterogeneity, additional sensitivity analyses/subgroup
analyses were performed according to publication type,
patient and disease characteristics, and methodological
quality of included studies (risk of bias and random error).
All analysis were performed using RevMan 5.1 [33] and
StatsDirect [34] software. This work is reported according
to the PRISMA guidelines [35].
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